Select Page ::

Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy fo | DDDT – Dove Medical Press

Posted on December 18, 2019 by Danzig

Liming Wang,1,* Shigao Huang,2,* Shimei Li,1 Ming Li,1 Jun Shi,1 Wen Bai,1 Qianyun Wang,1 Libo Zheng,3 Yongjun Liu3

1Cell Therapy Center, 986 Hospital of Peoples Liberation Army Air Force, Xian, Shaanxi, Peoples Republic of China; 2Cancer Center, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macao SAR, Peoples Republic of China; 3Stem Cell Biology and Regenerative Medicine Institution, Yi-Chuang Institute of Bio-Industry, Beijing, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Shigao HuangCancer Center, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Room 3013, Building N-22, Taipa, Macau, Peoples Republic of ChinaEmail huangshigao2010@aliyun.comYongjun LiuStem Cell Biology and Regenerative Medicine Institution, Yi-Chuang Institute of Bio-Industry, No. 35, Jinghai 3 Road Economic-Technological Development Area, Beijing, Peoples Republic of ChinaEmail andyliuliu2001@aliyun.com

Background: The traditional anti-inflammation disease-modifying anti-rheumatic drugs (DMARDs) have limited therapeutic effects in rheumatoid arthritis (RA) patients. We previously reported the safety and efficacy of umbilical cord mesenchymal stem cell (UC-MSC) treatment in RA patients that were observed for up to 8 months after UC-MSC infusion. The aim of this study is to assess the long-term efficacy and safety of UC-MSC along with DMARDs for the treatment of RA.Methods: 64 RA patients aged 1864 years were recruited in the study. During the treatment, patients were treated with 40 mL UC-MSC suspension product (2 107 cells/20 mL) via intravenous injection immediately after the infusion of 100 mL saline. The serological markers tests were used to assess safety and the 28-joint disease activity score (DAS28) and the Health Assessment Questionnaire (HAQ) to assess efficacy.Results: 1 year and 3 years after UC-MSC cells treatment, the blood routine, liver and kidney function and immunoglobulin examination showed no abnormalities, which were all in the normal range. The ESR, CRP, RF of 1 year and 3 years after treatment and anti-CCP of 3 years after treatment were detected to be lower than that of pretreatment, which showed significant change (P < 0.05). Health index (HAQ) and joint function index (DAS28) decreased 1 year and 3 years after treatment than before treatment (P < 0.05).Conclusion: UC-MSC cells plus DMARDs therapy can be a safe, effective and feasible therapeutic option for RA patients.

Keywords: rheumatoid arthritis, umbilical cord mesenchymal stem cell, cell therapy

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Aspen Neuroscience gets funding to pursue personalized cell therapy for Parkinsons disease – The San Diego Union-Tribune

Posted on December 18, 2019 by Danzig

Aspen Neuroscience, a new San Diego biotech company working on stem cell treatment for Parkinsons disease, has come out of stealth mode and raised $6.5 million to pursue clinical testing for its therapy.

Co-founded by well-known stem cell scientist Jeanne Loring, Aspen Neuroscience proposes creating stem cells from modified skin cells of Parkinsons patents via genetic engineering.

The stem cells, which can become any type of cell in the body, then would undergo a process that makes them specialize into dopamine-releasing neurons.

People with Parkinsons lose a large number up to 50 percent at diagnosis of specific brain cells that make the chemical dopamine.

Without dopamine, nerve cells cannot communicate with muscles and people are left with debilitating motor problems.

Once these modified skin cells have been engineered to specialize in producing dopamine, they can be transplanted into the Parkinsons patient to restore the types of neurons lost to the disease.

The reason we called it Aspen is because l was raised in the Rocky Mountain states, said Loring. When there is a forest fire in the Rockies, the evergreens are wiped out but the aspens are the fist that regenerate after the burn. So it is a metaphor for regeneration.

Aspen still has a long way to go before its proposed therapy would be available to Parkinsons patients. It has been meeting with the U.S. Food and Drug Administration to provide animal trial data and other information in hopes of getting permission to start human clinical trials.

But the company expects the earliest it would get the go-ahead from FDA to start human trials would be 2021.

Loring has been working on the therapy for eight years. She is professor emeritus and founding director of the Center for Regenerative Medicine at the Scripps Research Institute.

Loring co-founded the 20-employee company with Andres Bratt-Leal, a former post-doctoral researcher in Lorings lab at Scripps.

Joining them as Aspens Chief Executive is Dr. Howard Federoff, former vice chancellor for health affairs and chief executive of the University of California Irvine Health System.

Federoff said the company is the only one pursuing the use of Parkinsons patients own cells as part of neuron replacement therapy.

Aspens proprietary approach does not require the use of immuno-suppression drugs, which can be given when transplanted cells come from another person and perhaps limit the effectiveness of the treatment.

Aspens approach is a therapy that is likely to benefit from the fact that your own cells know how to make the best connections with their own target cells in the brain, even in the setting of Parkinsons disease, said Federoff. So when transplanted it is able to set back the clock on Parkinsons.

In addition to Aspens main therapy, it is researching a gene-editing treatment for forms of Parkinsons common in certain families.

Aspens research work up to now has been supported by Summit for Stem Cell, a non-profit on which provides a variety of services for people with Parkinsons disease.

The new seed funding round was led by Domain Associates and Axon Ventures, with additional participation from Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32.

Aspens financial backing, combined with its experienced and proven leadership team, positions it well for future success, said Kim Kamdar, a partner at Domain Associates. Domain prides itself on investing in companies that can translate scientific research into innovative medicines and therapies that make a difference in peoples lives. We clearly see Aspen as fitting into that category, as it is the only company using a patients own cells for replacement therapy in Parkinsons disease.

The rest is here:

Aspen Neuroscience gets funding to pursue personalized cell therapy for Parkinsons disease - The San Diego Union-Tribune

Aspen Neuro Bags $6.5M to Test Parkinson’s Disease Stem Cell Therapy – Xconomy

Posted on December 18, 2019 by Danzig

XconomySan Diego

Nearly nine years ago Jeanne Loring and her colleagues at Scripps Research debuted a test that leveraged advances in genomics and data science to determine, without testing in animals, whether human stem cells were pluripotent, or able to become any type of cell in the body.

Being able to prove that has become increasingly important as scientists look to induced pluripotent stem cells (iPSCs)mature, specialized cells that have been reprogrammed as immature cells, regaining the capability of becoming any type of cellas material for new regenerative medicines.

Now Loring and Andres Bratt-Leal, who joined her lab in 2012 as a post-doctoral researcher, have founded a biotech that combines stem cell biology and genomics know-how to advance a potential cell therapy for Parkinsons disease.

The startup announced Thursday it raised a seed round of $6.5 million to support its work. Aspens lead drug candidate, which is in preclinical testing, is intended to replace neurons in the brains of people with the disease, which causes those cells to become damaged or die.

When people with Parkinsons disease lose neurons, they also lose a chemical messenger the cells produce, called dopamine. Without dopamine, communication between nerve cells falters, which leads to the debilitating motor problems that characterize the disease. Existing Parkinsons drugs aim to alter dopamine levels. Aspen, however, wants to fix the upstream problem that leads to those lowered levels by reconstructing patients damaged neural networks.

The cell therapy would involve harvesting patients own living cells through a skin biopsy, reprogramming them to immature cells, or iPSCs, then further engineering them to become predisposed to mature into neurons. Once enough of those cells have been grown in the lab, those neuron precursor cells would be delivered directly to the brain.

Using a patients own cells avoids the dangerous immune system reactions that can occur when donor cells are used in such therapies, and obviates the need for immunosuppression drugs. Two cell therapies that use genetic engineering have been approved by the FDA, both of which take and tweak patients T cells into treatments for cancer. Stem cell transplants have been used to treat some cancers.

Aspen worked to ensure the company could ably manufacture a so-called autologous replacement cell therapy, or one from a patients one cells, by improving the process of differentiating iPSCs into dopamine neurons, Loring says. And the group developed another predictive genomic-based test, similar to the effort Loring spearheaded nearly a decade ago to determine whether cells were pluripotent, that can detect which iPSCs are destined to become neurons.

(Bratt-Leal) put his biological engineering expertise into coming up with a way that was reproducible, that we would get the same cells no matter who we got the original cells from, she says.

The company plans to test the therapy in patients that they determine, through genomic testing, have the most common form of Parkinsons, which is referred to as sporadic and arises without a clear genetic predisposition. It also has a second treatment in the works that it intends to develop for patients with familial forms of the disease, and uses a gene editing toolyet to be selectedto alter their stem cells during the reprogramming process.

Howard Federoff, who was most recently vice chancellor for health affairs and CEO of the UC Irvine Health system, is Aspens CEO. Federoff says he has come to believe that Parkinsons patients need more than just to stabilize their disease They need to turn the clock back.

Many companies are working on drugs to treat Parkinsons, but most are meant to manage symptoms rather than reverse the disease. Levodopa, which supplants missing dopamine, is used widely, but it can cause side effects, including involuntary movement called dyskinesia; and, as the disease progresses, the drug eventually stops working between doses.

Aspen claims it is the only company working toward an autologous neuron replacement. The company, however, will need to raise a Series A round to move its drug candidates through Phase 2 proof-of-concept trials, Loring says.

The company raised its seed round from a group of investors including Domain Associates, Alexandria Venture Investments, Arch Venture Partners, Axon Ventures, OrbiMed, and Section 32. Initially, it was financed through grants from Summit for Stem Cell, a San Diego-based nonprofit.

Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com.

Aspen Neuro Bags $6.5M to Test Parkinson's Disease Stem Cell Therapy - Xconomy

Global Allogeneic Stem Cells Market 2020-2024 | Evolving Opportunities with Biosolution Co. Ltd. and Cynata Therapeutics Ltd. | Technavio – Business…

Posted on December 18, 2019 by Danzig

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global allogeneic stem cells market and the market is poised to grow by USD 1.24 billion during 2020-2024 at a CAGR of over 12% during the forecast period. Request Free Sample Pages

Read the 131-page research report with TOC on "Allogeneic Stem Cells Market Analysis Report by geography (Asia, Europe, North America, and ROW), by application (regenerative therapy and drug discovery and development), and segment forecasts, 2020-2024".

https://www.technavio.com/report/allogeneic-stem-cells-market-industry-analysis

The new product approvals and special drug designations are anticipated to boost the growth of the market. Based on the application, the allogeneic stem cells market has been segmented into regenerative therapy and drug discovery and development. Manufacturers are increasingly emphasizing innovations and improvisation in the development of regenerative therapies. Many of the regenerative therapeutic candidates have obtained approval for clinical trials in the US, Europe, and APAC due to the efficacy of allogeneic stem cell therapeutics. This is encouraging market players to launch new product lines to stimulate the overall product demand for stem or regenerative therapy using allogeneic stem cell therapeutics and provide better options for their customers. Thus, new product approvals are expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Allogeneic Stem Cells Market Companies:

Biosolution Co. Ltd.

Biosolution Co. Ltd. is headquartered in South Korea (Republic of Korea) and operates the business under its Unified business segment. The company offers an allogeneic keratinocyte spread medication, Keraheal-Allo, that promotes skin regeneration.

Cynata Therapeutics Ltd.

Cynata Therapeutics Ltd. is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sales of innovative therapeutics for the treatment of various diseases. The company provides a mesenchymal stem cell product, Cymerus, which is used to treat graft-versus-host disease.

JCR Pharmaceuticals Co. Ltd.

JCR Pharmaceuticals Co. Ltd. is headquartered in Japan and operates under two business segments, namely Pharmaceuticals, and Medical Devices and Laboratory Equipment. The company offers a regenerative medical product, TEMCELL HS Injection, which uses human mesenchymal stem cells for the treatment of acute graft-versus-host disease.

Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc. is headquartered in the US and offers products through its Unified business segment. The company provides OpRegen, which is currently being tested in a Phase I/IIa clinical trial. This product is intended for the treatment of dry AMD.

MEDIPOST Co. Ltd.

MEDIPOST Co. Ltd. is headquartered in South Korea (Republic of Korea) and offers products through its Unified business segment. The company provides an allogeneic umbilical cord blood-derived mesenchymal stem cell drug, CARTISTEM, which is used for the treatment of knee cartilage defects.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Allogeneic Stem Cells Application Outlook (Revenue, USD Million, 2020-2024)

Allogeneic Stem Cells Regional Outlook (Revenue, USD Million, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care include:

Cancer Stem Cell Therapeutics Market Global Cancer Stem Cell Therapeutics Market by type (allogeneic stem cell transplant and autologous stem cell transplant) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Continue reading here:

Global Allogeneic Stem Cells Market 2020-2024 | Evolving Opportunities with Biosolution Co. Ltd. and Cynata Therapeutics Ltd. | Technavio - Business...

BioRestorative Therapies Featured in IEEE Pulse Magazine’s Cover Story About Stem Cell Therapies for Low Back Pain – GlobeNewswire

Posted on December 18, 2019 by Danzig

MELVILLE, N.Y., Dec. 16, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (BioRestorative or the Company) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today feature coverage in the news outlet, IEEE Pulse, a magazine of the IEEE Engineering in Medicine and Biology Society. According to IEEE, it is the worlds largest technical professional organization for the advancement of technology.

To view the IEEE Pulse Magazines article featuring BioRestorative, click here.

The published cover-story article features commentary from Francisco Silva, Chief Scientist and Vice President of Research and Development for BioRestorative, regarding BRTX-100, the Companys lead therapeutic candidate for chronic lumbar disc disease. Once the U.S. Food and Drug Administration (FDA) authorizes the sale of BRTX-100, we would ship it to your doctor, and with a 30-minute procedure the material would be injected into your disc in a 1.5 ml solution, explains Silva. He elaborates on the product, discussing growing and expanding stem cells from the patients bone marrow under hypoxic conditions that mimic those in the normal intervertebral space. We are enriching the cells to be able to survive in this harsh environment, says Silva.

In addition to BRTX-100, the magazine article also highlights BioRestoratives other research pursuit, its ThermoStem program, utilizing brown adipose (fat) derived stem cells to target treatment of metabolic diseases and disorders, like diabetes, obesity and hypertension.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs.

Metabolic Program (ThermoStem): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, whether the Company will be able to consummate the private placement and the satisfaction of closing conditions related to the private placement and those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:Email: ir@biorestorative.com

Read the original post:

BioRestorative Therapies Featured in IEEE Pulse Magazine's Cover Story About Stem Cell Therapies for Low Back Pain - GlobeNewswire

Regenerative Stem Cell Therapy With Novita Spa On The Square Medical Rejuvenation Clinic – KXAN.com

Posted on December 18, 2019 by Danzig

The Groundbreaking Series That Puts Innocent Civilians in Jail Returns For Its Most Dangerous Season Yet

For the first time in "60 Days In" history, more participants struggle to survive the intense program and are forced to quit early. After two decades, the Etowah County Detention Center is under new management and the new Sheriff is determined to make a change. In his first week, he decided to shakedown the facility and in one day alone, found more than 200 broken door locks, drugs and removed more than two tons of contraband. With no time to lose, Sheriff Horton along with Chief Peek and select members of their team have agreed to embed innocent participants to uncover the issues that plague the facility. This season, the participants will face the biggest challenge of their lives in an effort to rid a jail, that is in dire need of help, of contraband and corruption before it is too late.

View original post here:

Regenerative Stem Cell Therapy With Novita Spa On The Square Medical Rejuvenation Clinic - KXAN.com

Scientists Take Stem Cells and Convert Them to Heart Pacemaker Cells – Technology Networks

Posted on December 18, 2019 by Danzig

University of Houston associate professor of pharmacology Bradley McConnell is helping usher in a new age of cardiac pacemakers by using stem cells found in fat, converting them to heart cells, and reprogramming those to act as biologic pacemaker cells. He is reporting his work in theJournal of Molecular and Cellular Cardiology.

The new biologic pacemaker-like cell will be useful as an alternative treatment for conduction system disorders, cardiac repair after a heart attack and to bridge the limitations of the electronic pacemaker.

"We are reprogramming the cardiac progenitor cell and guiding it to become a conducting cell of the heart to conduct electrical current," said McConnell.

McConnell's collaborator, Robert J. Schwartz, Hugh Roy and Lillian Cranz Cullen Distinguished Professor of biology and biochemistry, previously reported work on turning the adipogenic mesenchymal stem cells, that reside in fat cells, into cardiac progenitor cells. Now those same cardiac progenitor cells are being programmed to keep hearts beating as a sinoatrial node (SAN), part of the electrical cardiac conduction system (CCS).

The SAN is the primary pacemaker of the heart, responsible for generating the electric impulse or beat. Native cardiac pacemaker cells are confined within the SAN, a small structure comprised of just a few thousand specialized pacemaker cells. Failure of the SAN or a block at any point in the CCS results in arrhythmias.

More than 600,000 electronic pacemakers are implanted in patients annually to help control abnormal heart rhythms. The small mechanical device is placed in the chest or abdomen and uses electrical pulses to prompt the heart to beat normally. In addition to having the device regularly examined by a physician, over time an electronic pacemaker can stop working properly.

"Batteries will die. Just look at your smartphone," said McConnell. "This biologic pacemaker is better able to adapt to the body and would not have to be maintained by a physician. It is not a foreign object. It would be able to grow with the body and become much more responsive to what the body is doing."

To convert the cardiac progenitor cells, McConnell infused the cells with a unique cocktail of three transcription factors and a plasma membrane channel protein to reprogram the heart cells in vitro.

"In our study, we observed that the SHOX2, HCN2, and TBX5 (SHT5) cocktail of transcription factors and channel protein reprogrammed the cells into pacemaker-like cells. The combination will facilitate the development of cell-based therapies for various cardiac conduction diseases," he reported.

Reference: Raghunathan et al. (2019).Conversion of human cardiac progenitor cells into cardiac pacemaker-like cells. Journal of Molecular and Cellular Cardiology. DOI: https://doi.org/10.1016/j.yjmcc.2019.09.015.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Here is the original post:

Scientists Take Stem Cells and Convert Them to Heart Pacemaker Cells - Technology Networks

Orbiting Organoids: Research in Space to Unveil New Neurodegeneration Insight – Xconomy

Posted on December 18, 2019 by Danzig

XconomyNational

More than 250 miles above the Earths surface aboard the International Space Station, a first-in-kind study of neurodegenerative disease is expected to reveal never-before-seen cell interactions.

The National Stem Cell Foundation (NSCF) is funding the study, which is the result of a bi-coastal collaboration between the New York Stem Cell Foundation (NYSCF) Research Institute and Aspen Neuroscience, a San Diego startup developing personalized cell therapies for Parkinsons disease.

Collaborating with the New York Stem Cell Foundation (NYSCF) Research Institute on the other side of the country, the two teams have been working together for more than two years, exchanging and sharing technology to develop patient-derived, induced pluripotent stem cell (iPSC) organoid models.

The 3D human organoid models were launched to the International Space Station earlier this month for research in microgravity, with the goal of furthering our understanding of neurogenerative diseases back on earth.

The models incorporate microglia, the inflammatory cells of the immune system that are implicated in the development of Parkinsons, multiple sclerosis, and other neurodegenerative diseases, explains Paula Grisanti, CEO of NSCF.

Studying the 3D models in microgravity, researchers are able to observe cell interaction, gene expression, and other developments not seen in a regular lab.

Its not possible for you to have this same 3D model of cell interaction on Earth. This will be the first time in space where we can see these in 3D, Grisanti tells Xconomy.

Cells behave differently in space, though its not completely understood why. Cartilage grows faster and bigger, proteins fold differently, and cells mature more rapidly. Being able to see this happen in real-timethe models will be filmed for the full 30 dayswill offer researchers unprecedented insight into neurodegenerative disease.

To see how those cells talk to each other for 30 days when they are up on the international space station will allow scientists to see the point at which things start to go awry in those diseases and hopefully identify a new place or a new point at which you could intervene with a cell or gene therapy that may or may not currently exist, says Grisanti.

The research will touch back down to earth in early January at which time both labs will analyze the models to determine what exactly happened during their time in space. All data will be published for full dissemination.

(Paul Kuehl, Jason Rexroat, Gentry Barnett, Valentina Fossati, Jason Stein, Scott Noggle, Jana Stoudemire. Image courtesy of Space Tango)

NSCF has budgeted for a year of post-flight research after which the researchers will send the models back to the space station for a second flight to confirm what they saw and test new hypotheses, explains Grisanti. A second year of post-flight research also is funded, as is a second flight at the end of 2020.

We know were going to see something new because it has never been done before, says Grisanti, who explains that the budget and project will continue to be extended as long as new theories and opportunities are being developed.

The December flight was the second for the research teams at Apsen and NYSCF. A preliminary flight was conducted in July 2019 to test the hardware systems and prepare for the SpaceX CRS-19 launch.

Aspen has also been pressing ahead with its own research on solid ground. Last week, the company closed a $6.5 million seed round led by Domain Associates and Axon Ventures.

Aspens cell therapy approach was developed by its co-founders, Jeanne Loring, professor emeritus and founding director of the Center for Regenerative Medicine at The Scripps Research Institute and Andres Bratt-Leal, a former post-doctoral researcher in Lorings lab. Also serving as Aspens chief scientific officer, Jeanne Loring was in May named Xconomys Stem Cell Pioneer of the Year.

(Main image: Experiment loaded for launch at Kennedy Space Center. Courtesy of Space Tango)

Melissa Fassbender is an Xconomy editor based in Chicago. You can reach her at mfassbender@xconomy.com.

Orbiting Organoids: Research in Space to Unveil New Neurodegeneration Insight - Xconomy

Stem Cell Therapy Market Detailed Analysis and Forecast 2017-2025 – 101Newsindustry

Posted on December 18, 2019 by Danzig

Stem Cell Therapy Market: Snapshot

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

To know Untapped Opportunities in the MarketCLICK HERE NOW

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Get Discount on Latest Report @CLICK HERE NOW

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Read the original post:

Stem Cell Therapy Market Detailed Analysis and Forecast 2017-2025 - 101Newsindustry

Global Stem Cell Therapy Market to Become a Worth US$ 4759.27 Million By 2024 – E-Industry News

Posted on December 18, 2019 by Danzig

The Global Stem Cell Therapy Market Set For Rapid Growth, To Reach Around USD 4759.27 Million By 2024Research Report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability.The global Stem Cell Therapy Market report is a systematic study of the globalStem Cell Therapy Marketintroducing the advanced state of affairs in the market as well as schemes that aid in its enlargement in the coming years. The report evaluates several factors determining the market expansion as well as the volume of the whole Stem Cell Therapy Market. The report states the aggressive vendor scenery of the market together with the profiles of some of the leading market players. The most important players in the Stem Cell Therapy Market are also discussed in the report.

This Research will help you grow your Business: [Download free Sample PDF of This Research Report]

Some of the Major Stem Cell Therapy Market Players Are:

The report covers the product contributions, revenue generated, segmentation, and business summarization of the foremost players. The report provides data taking into consideration the latest improvements in the global Stem Cell Therapy Market while estimating the contribution in the market of the most important players in the near future. The report estimates the limitation and power of the leading players via SWOT analysis and assesses their growth in the market. Additionally, the key product categories and segments as well as the sub-segments of the global market are clarified in the report.

The market assessment is also estimated throughout the research as well as concludes the data using Porters five analysis on the market enlargement.Further, the report also scrutinizes the Stem Cell Therapy Market based on the manufactured goods categories and customer segments as well as the development of each segment is calculated over the predicted time.

Request Free research report Brochure @https://www.zionmarketresearch.com/requestbrochure/stem-cell-therapy-market

The report collects information accumulated from various authoritarian organizations to estimate the growth of the segments. Additionally, the study also evaluates the global Stem Cell Therapy Market on the basis of the topography and analyzes the macro- and microeconomic features determining the market expansion in every area. Furthermore, the Stem Cell Therapy Market is classified on the basis of various regions.

The Stem Cell Therapy Market segmented by regions/countries:

Browse Press Release:https://www.zionmarketresearch.com/news/stem-cell-therapy-market

Highlights of Stem Cell Therapy Market Report:

1) Global Stem Cell Therapy Market share & sales assessments on the basis of regional and country level segments.

2) Industry share analysis of the top market players.

3) Strategic recommendations for the new companies.

4) Market forecasts for 5 years of all the mentioned segments, sub segments and the regional markets.

5) Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations).

6) Competitive landscaping mapping the key trends.

7) Company profiles with their strategies, financials, and recent developments.

8) Production Supply chain trends analysis latest technological advancements.

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/stem-cell-therapy-market

Objective of Studies:

1. To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Stem Cell Therapy Market.

2. To provide insights about factors affecting the market growth. To analyse the Stem Cell Therapy Market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc.

3. To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and Rest of the World.

4. To provide country level analysis of the market with respect to the current market size and future prospective.

5. To provide country level analysis of the market for segment by application, product type and sub-segments.

6. To provide strategic profiling of key players in the market, comprehensively analysing their core competencies, and drawing a competitive landscape for the market.

7. To track and analyse competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Stem Cell Therapy Market.

Why Trust ZMRs Analytical Insights?

Target Audience of Stem Cell Therapy Market:

Manufacturer / Potential Investors

Traders, Distributors, Wholesalers, Retailers, Importers and Exporters

Association and government bodies

Also, Research Report Examines:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Link:

Global Stem Cell Therapy Market to Become a Worth US$ 4759.27 Million By 2024 - E-Industry News

Cell Culture Protein Surface Coating Market To Reach USD 659.1 Million By 2026 | Reports And Data – GlobeNewswire

Posted on December 18, 2019 by Danzig

New York, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Increasing interest of biotechnology companies and scientists in cancer and stem cell research, rising commercial production of biologics like proteins, antibodies and vaccines & drugs have boosted the cell culture market because of which cell culture protein surface coating market has also seen a proportional growth.

According to the current analysis of Reports and Data, the global cell culture protein surface coating market was valued at USD 238.3 million in 2018 and is expected to reach USD 659.1 million by the year 2026, at a CAGR of 13.6%. Cell culture is a process in which cells are grown under controlled physical environment outside their natural environment. Cell culture protein surface coating helps to improve adhesion and growth of in vitro cell culture. These cells are helpful in developing model systems for research, studying cellular functions, stem cell research, drug discovery, and genetic engineering. The growing scope of associated culture industry across the globe has helped the market for cell culture protein surface coating grow.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/2265

With incidents of chronic diseases on the rise around the world, the research, drug development, and clinical trials on various therapies also need to be increased. Therefore, the demand for target industry usage will also have a boost. This will be a significant factor fuelling the growth of this industry. It also helps in cell isolation, which plays a very vital role in the diagnostics and research of chronic diseases. It helps in drug discovery by studying the behavior of the cells and their response to disease and drugs. This technique of drug discovery helps to generate medicines that can be used for the treatment of various diseases such as cancer, genetic disorders, and autoimmune diseases. All these factors have contributed towards a positive dynamic growth curve of this industry, and it is expected to keep growing in the coming years.

North America is recognized for its healthcare-related culture laboratories and research funding. The National Institutes of Health (NIH) extensively finance stem cell research in the United States each year. Moreover, the National Cancer Institute (NCI) allocates high funding for research into cancer disorders and personalized medicine to institutions and companies working with research centers. These aspects boost the significance of cell culture activities. The healthcare expenditure is, therefore, high in the United States and Canada.

Furthermore, improving government initiatives, availability of research funds from private as well as public bodies, and rising awareness about the benefits of this technology are among the key factors propelling the growth of the target market.

Further key findings from the report suggest

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/cell-culture-protein-surface-coating-market

Segments covered in the report:

For the purpose of this study, Reports and Data have segmented the cell culture protein surface coating market on the basis of coating type, protein source, end use and region:

Coating Type (Revenue in USD Billion, 2018 - 2026)

Protein Source (Revenue in USD Billion, 2018 - 2026)

Order Now: https://www.reportsanddata.com/checkout-form/2265

Regional Outlook (Revenue in USD Million; 20162026)

Browse more similar reports on Diagnostics category by Reports And Data

Photomedicine Market - https://www.reportsanddata.com/report-detail/photomedicine-market

In-Vitro Diagnostics (IVD) Quality Control Market - https://www.reportsanddata.com/report-detail/in-vitro-diagnostics-ivd-quality-control-market

Point of Care (PoC) Diagnostics Market - https://www.reportsanddata.com/report-detail/point-of-care-poc-diagnostics-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

See more here:

Cell Culture Protein Surface Coating Market To Reach USD 659.1 Million By 2026 | Reports And Data - GlobeNewswire

AI and the future of work: becoming cyborgs! – Ericsson

Posted on December 18, 2019 by Danzig

Mum, when I grow up, I want to be a police officerno, a soccer playerno, a scientist!

Ok darling, that sounds great! But how about becoming a cyborg?

As intelligent machines become increasingly common and powerful things are going to change, especially for those of us in the workforce. To prepare ourselves for the future, we need to learn how to work together with these machines. How can we get the best out of machines, and work together as a seamless team? Or, in a sense, how can we become cyborgs?

Its not just down to the individual to figure out how to transform into an AI-human hybrid. Organizations need to create environments that foster these alliances. So, if your position involves creating jobs, or hiring and managing people, this blog post is for you.

Here, I propose some crucial questions that you should ask in order to future-proof your workplace.

When it comes to discussing AI and the future of work we exhale in relief when someone says machines will have a hard time replacing us. This statement is backed by the argument that most AI systems are narrow. This is when AI systems only do one thing but do it really well, for example, predicting what you want to watch on Netflix. If you ask the same system to make you a cup of coffee or drive your car, youre likely to be disappointed. Similarly, when it comes to work the expectation is that AI can take over certain tasks, but perhaps not entire multidisciplinary roles.

But what happens when the AI system can perform the most significant tasks that a job entails? In our report about creative machines, we looked at how AI can impact work life. One interesting example we found came from the fashion industry, where a company had implemented two AI systems to produce novel designs. Together, the machines did all work, from trend scouting to creating new designs, and predicting how well they would sell. The first human intervention didnt occur until the designs were sent to production. In short, the humans role was to surveil the system.

The AI proved to be successful, but how much fun did the human overseer really have? Especially if they were an educated designer capable of creating new designs by themselves...

For future jobs, we need to learn how the humans role can evolve beyond supervisor, and how we can we draw on human strengths to improve AI systems. Most importantly, we need to ensure that work conducted alongside AI is still perceived as meaningful.

If you dont figure this out, youre unlikely to attract the most talented people in the future.

Lets say you find a way to make working with a machine both meaningful and attractive. How do you make sure your team becomes good at it?

Research published earlier this year coined the term Shadow Learning. As explained in the Harvard Business Review article titled Learning to work with intelligent machines, the researcher studied the challenges new surgeons faced when learning robotic surgery skills. Previously, they learned how to perform surgery by working alongside expert surgeons, but now theyre forced to watch over the surgeons shoulder as, thanks to robotics, individuals can handle entire surgeries with one pair of hands resulting in fewer hands-on learning opportunities for the student.

The term, however, does not mean that you learn by shadowing someone. The phrase refers to students who gained experience with robotic tools by taking it upon themselves to acquire new skills outside of the curriculum. Some students, for instance, used simulation tools or watched videos of robotic surgery on YouTube (what cant you learn from YouTube?). This, however, often forced the students to skip other crucial parts of the course.

For creating the AI-human workforce of the future we need to ensure that there are enough learning opportunities. So, how do you foster continuous learning and create chances for machine-human teams to excel?

See this as an opportunity. When trying to attract future star employees, offering them a chance for professional development and exposure to new technologies will give you a competitive edge against other employers.

We often say that ensuring trust in the machines is crucial. However, overreliance on AI systems could become an issue, especially during decision-making. If you always have an intelligent assistant aiding you it could get harder to ignore its advice. The smarter it gets, the harder it would be to argue against it. It may even lead to increased mental obesity, where humans just ask the AI and mindlessly follow its instructions. I have also previously written about this in another post about mental obesity and AI. In another post, my colleague also writes about the effects of overdependence on technology where he notes the typically western habit of taking the escalators rather than the stairs, its just so easy to let the machine do the work.

Overreliance on AI systems could also lead to bolder decisions, as we saw in one of our public safety studies. This insight later turned into another hot consumer trend, as our researched showed that people who perceive their smartphone as a safety device knowingly take greater risks when they have their smartphone with them. Translating this into an organizational setting, its fair to raise the question: will people be more open to taking risks if they believe a system will always be there to aid them? Is it possible that theyll also reflect less on the consequences of AI-guided decisions?

We should be augmented by the machines that we work with, not pacified. But how can you support critical thinking and autonomy at work when employees are aided by intelligent machines?

Finding the sweet spot of trust and reliance in the AI-Human collaboration you will not only inspire and empower your employees to take informed decisions, you will probably also stimulate people to generate more novel ideas.

If we look beyond the current discussion of AI and the future of work which usually revolves around the number of jobs that will be impacted by AI we can focus on how to create inspiring new ways to work with machines.

To get there, we need to figure out how to foster new alliances and bring out the best in both AI and humans.

This is a great opportunity. Just imagine what you can do when your employees are motivated, well trained and empowered. Imagine having Cyborgs!

Visit our IndustryLab and ConsumerLab pages to read more about how technology will impact our lives in the coming years.

Link:

AI and the future of work: becoming cyborgs! - Ericsson

Watchmen: Damon Lindelof On Why There Were 9 Episodes Instead Of 10 – Heroic Hollywood

Posted on December 18, 2019 by Danzig

Damon Lindelof reveals why the first season of HBOsWatchmenended up having 9 episodes rather than its original 10.

In an interview with Collider, Damon Lindelof revealed that following the events of the sixth episode entitled This Extraordinary Being, where Regina Kings Angela Abar takes her grandfathers nostalgia pills, the writing team couldnt stretch the story to 10 episodes for this season so it was cut down by one episode for narrative reasons.

You can read Damon Lindelofs explanation for cuttingWatchmendown to 9 episodes rather than 10 down below:

The original plan was to do 10. And, then, I think around the time that we had written the scripts for four and five, and understanding what episode six was going to beand six needed to happen exactly when it happened in the season, in our opinionthat we felt like once six ended, that we were closer to the ending than we were to the beginning. Six didnt feel like a mid point. It felt like, we now know everything that we need to know to move into the endgame. And, every way that we looked at it, it felt like if we were going to do seven, eight, nine and ten, one of those episodes was going to be filler. And I was like, Were just not doing the filler episode. We know exactly what we need to do in our endgame. Its time to start doing it. I dont want to stall.'

Damon LindelofsWatchmenhas received universal acclaim from critics, with much of the praise given to the writing on display. Based on this decision to cut down one episode from the original 10-episode plan, Damon Lindelof wanted to make sure that there was no excess to the story. And based on how the product turned out, this was certainly the right decision creatively.

What do you make of this? Do you think it was wise forWatchmento cut down on one episode to avoid unnecessary filler? Sound off in the comments below, and be sure to continue following Heroic Hollywood for all the latest news on Damon LindelofsWatchmenand more of HBOs hit series.

Here is the synopsis for Damon LindelofsWatchmen:

Set in an alternate history where superheroes are treated as outlaws, WATCHMEN embraces the nostalgia of the original groundbreaking graphic novel while attempting to break new ground of its own.

Watchmenstars Regina King, Jeremy Irons, Don Johnson, Jean Smart, Tim Blake Nelson, Louis Gossett Jr., Yahya Abdul-Mateen II, Hong Chau, Andrew Howard, Tom Mison, Frances Fisher, Jacob Ming-Trent, Sara Vickers, Dylan Schombing, and James Wolk.

Source: Collider

Along with the premiere of the first teaser forDoom Patrol,DC Universe also debuted a collection of character posters for each of the members of perhaps the strangest team of characters to be adapted in live-action form for DC Comics.

In particular, these new character posters highlight Timothy Dalton's The Chief, Diane Guerrero's Crazy Jane, Joivan Wade's Cyborg, April Bowlby's Elasti-Woman, Matt Bomer's Negative Man and Brendan Fraser's Robotman. These posters each follow unique designs that reflect the nature of each character and tease unique personalities amongst the group as well.

You can start the gallery of new posters by clicking "Next".

Which of theseDoom Patrolposters is your favorite? Are you excited to see what the cast brings to these roles? Sound off in the comments below, and be sure to continue following Heroic Hollywood for all the latest news in the DC Universe.

Doom Patrol is a reimagining of one of DCs strangest group of outcast Super Heroes which includes: Matt Bomer as Larry Trainor/Negative Man, Brendan Fraser as Cliff Steele/Robotman, April Bowlby as Elasti-Woman, Diane Guerrero as Crazy Jane, Joivan Wade as Victor Stone/Cyborg and Timothy Dalton as Dr. Niles Caulder/The Chief.

Here is the synopsis for the show:

Doom Patrolwill find the reluctant heroes in a place they never expected to be, called to action by Cyborg, who comes to them with a mission hard to refuse, but with a warning that is hard to ignore: their lives will never, ever be the same.

Doom Patrolwill premiere on February 15, 2019 exclusively on DC Universe.

Go here to see the original:

Watchmen: Damon Lindelof On Why There Were 9 Episodes Instead Of 10 - Heroic Hollywood

Canadian featherweight Felicia Spencer returns to action on UFC card in Norfolk – The Chronicle Journal

Posted on December 18, 2019 by Danzig

TORONTO - Canadian Felicia (Feenom) Spencer looks to bounce back from a July loss to former UFC featherweight champion Cris Cyborg when she takes on France's Zarah (Infinite) Fairn on Feb. 29 in a televised UFC card in Norfolk, Va.

Spencer, 29, lost a unanimous decision to Cyborg at UFC 240 in Edmonton. Cyborg has since moved to the Bellator promotion and will take on Canadian featherweight champion Julia (The Jewel) Budd in January.

Spencer (7-1-0) is 1-1 since joining the UFC. The Montreal native, who trains in Orlando, Fla., won her debut in May when she choked out Australian Megan Anderson in Rochester, N.Y., in a matchup of former Invicta FC featherweight champions.

Fairn, 33, is coming off a loss to Anderson at UFC 243 in October.

This report by The Canadian Press was first published Dec. 18, 2019.

Go here to see the original:

Canadian featherweight Felicia Spencer returns to action on UFC card in Norfolk - The Chronicle Journal

The Witcher: Henry Cavill Says Show Won’t Block Him From Superman Role – Heroic Hollywood

Posted on December 18, 2019 by Danzig

The Witcherstar Henry Cavillclaims that his role as Geralt of Rivia shouldnt interfere with him playing Superman again.

Warner Bros. Pictures and DC Films currently has a slate of new films coming out within the next decade already, but many fans are wondering when another Superman film will get made, and if so, would Henry Cavill reprise his role he originated from Zack SnydersMan of Steel.

In an interview with Radio Times, Henry Cavill reiterated that despite his busy schedule withThe Witcher,he should be able to squeeze in another project to work on in the same year, leaving a possible opening to play Superman again if given the opportunity to do so:

Youve got to keep in mind that regardless of what movies Ill be doing over the next few years, you can fit two projects into one year.

Given the uncertain future regarding his reign as Superman on the big screen, Henry Cavill was asked about whether or not he had any hope left in playing the Man of Steel for a fourth time, to which he referenced Supermans emblem as portrayed in Man of Steel:

I mean, thats what it stands for, right?

Do you hope Henry Cavill will have the opportunity to play Superman again even with his busy schedule withThe Witcher?Sound off in the comments below, and be sure to continue following Heroic Hollywood for all the latest news on the future of Henry Cavills Superman.

Here is the official synopsis for Henry CavillsThe Witcher:

Based on the best-selling fantasy series, The Witcher is an epic tale of fate and family. Geralt of Rivia, a solitary monster hunter, struggles to find his place in a world where people often prove more wicked than beasts. But when destiny hurtles him toward a powerful sorceress, and a young princess with a dangerous secret, the three must learn to navigate the increasingly volatile Continent together.

The Witcherstars Henry Cavill as Geralt of Rivia, Freya Allan as Ciri, Anya Chalotra as Yennefer, Jodhi May as Queen Calanthe, Bjorn Hlynur Haraldsson as Eist, Adam Levy as Mousesack, MyAnna Buring as Aretuza, and Millie Brady as Princess Renfri, with Mimi Ndiweni and Therica Wilson-Read as novice sorcerers.

The Witcherwill be available on Netflix on December 20, 2019.

Source: Radio Times

You can start the gallery of new posters by clicking "Next".

Here is the synopsis for the show:

Doom Patrolwill premiere on February 15, 2019 exclusively on DC Universe.

Here is the original post:

The Witcher: Henry Cavill Says Show Won't Block Him From Superman Role - Heroic Hollywood

UFC 245 odds, fight card: A closer look at every bout from the early prelims to the main event – CBS Sports

Posted on December 18, 2019 by Danzig

The final UFC pay-per-view event of the year on Saturday night in Las Vegas is set to deliver us one of the most loaded fight cards of the year as 2019 comes to a close and 2020 looms on the horizon. With not one ... not two ... but three championship fights set to take place, you'd be hard-pressed to find an MMA fan out there that isn't eagerly awaiting the UFC 245 festivities this weekend.

The main event features one of the most anticipated rivalries in the sport coming to a head while the co-main and co-feature will showcase two of UFC's top champions returning to action. Plus, this card also features the return of some legendary names on the main card and some fast-rising prospects on the prelims.

Can't get enough UFC? Subscribe to our podcast State of Combat with Brian Campbell where we break down everything you need to know in the Octagon, including a complete preview of UFC 245 below.

With so much to look forward to, we at CBS Sports took the time to give you a breakdown of every fight on the card. Let's take a closer look at each bout to come on Saturday night from Sin City with some background on each fighter.

(Odds via MGM)

Oskar Piechota -115 vs. Punahele Soriano -115, middleweights: After an 11-0-1 start to his career that only saw two fights reach the judges' scorecards, Piechota (11-2-1) has lost back-to-back fights. Making matters worse, both fights -- against Gerald Meerschaert and Rodolfo Vieira -- ended in submission losses. Soriano (6-0) will be making his official Octagon debut after earning his way to the UFC with a win on Dana White's Contender Series. That fight was the only in his career to end in decision, with two submissions and three knockouts coming previously.

Viviane Araujo -170 vs. Jessica Eye +140, women's flyweights: Eye (14-7) started her UFC career with a win over Sarah Kaufman that was overturned due to a positive drug test for marijuana metabolites. She then lost five of her next six fights, with every loss coming via decision against some top names in the division. Eye then dropped to flyweight and the UFC's decision to keep her around despite the move coming after a four-fight losing skid paid off. With three straight wins, Eye received a title shot against Valentina Shevchenko, but lost via second-round head kick knockout. Araujo (8-1) doesn't share as dramatic a ride in her UFC career, simply entering the UFC on a three-fight win streak before Octagon wins over Talita Bernardo and Alexis Davis ran that streak to five. Her May knockout of Bernardo was a highlight reel display of power.

Kai Kara-France -160 vs. Brandon Moreno +130, flyweights: Kara-France (20-7) enters the fight as the No. 6 ranked flyweight in the CBS Sports UFC divisional rankings. After a 7-6 start to his career, he has gone on a 13-1 run as his competition has gotten better and the lights have gotten brighter. Making his Octagon debut one year ago, Kara-France has won three straight decisions in the UFC. Moreno (15-5-1) has spent more than three years as a member of the UFC roster. After three wins to kick off his career, he has a 1-2-1 record in his four most recent fights. His most recent bout was a draw against Askar Askarov.

Chase Hooper -130 vs. Daniel Teymur +100, featherweights: Teymur (7-3) made his way to the UFC after a 6-0 start to his career and things quickly went wrong. He lost his first three UFC bouts, two by rear-naked choke. He finally turned things around in June with a decision win over Sung Bin Jo. Hooper (8-0-1) is an undefeated 20-year-old prospect set to make his UFC debut on one of the biggest cards of the year. He has won two fights by submission, four by knockout and has only seen the judges's scorecards three times, once battling to a draw.

Matt Brown -360 vs. Ben Saunders +290, welterweights: It seems almost impossible Brown (21-16) and Saunders (22-12-2) have never fought in the UFC. With a combined 42 UFC fights, it seems the two always-game competitors would have crossed paths by now. Brown has been fighting in the Octagon since June 2008, but he has not fought since November 2017 due to an ACL injury and associated rehabilitation. Saunders made his UFC debut in December 2007 and after seven fights was let go from the promotion with a two-fight losing skid. It took four years before he battled his way back to the UFC in August 2014, winning his first three fights back. Saunders is currently on a three-fight losing skid and a 1-5 run.

Ian Heinisch -150 vs. Omari Akhmedov +120, middleweights: Middleweight is a tough division to crack into the top 10, but these are the kind of fights that place the winner on the verge of earning their way onto the list. Akhmedov (19-4-1) has been fighting in the UFC for more than six years and has only suffered three defeats. He's on a five fight unbeaten streak that includes four decision wins and a draw. Heinisch (13-2) had a five-fight winning streak snapped in his most recent bout, a decision loss to Derek Brunson in August.

Ketlen Vieira -185 vs. Irene Aldana +155, women's bantamweights: With a women's bantamweight title fight as one of the night's headliners, Vieira (10-0), ranked No. 3 in the CBS Sports rankings, may be just one win away from punching her ticket into a fight with the winner. She continued her unbeaten ways once joining the UFC, winning four consecutive bouts, though not always convincingly. Two of her Octagon victories have come via split decision. No. 9 ranked Aldana (11-5) doesn't have as sparkling a record as Vieira, but she has faced some big names in the Octagon and has a 4-3 record.

Geoff Neal -250 vs. Mike Perry +200, welterweights: Perry (13-5) made a splash in the UFC with his big power punching style. He won four of his first five UFC bouts, all by knockout. As the competition increased, the knockouts -- and wins -- stopped. After his blazing start to his UFC career, Perry has gone on a 2-4 skid. Neal (12-2) has been perfect over his six most recent fights, which include four in the UFC. Nine of his 12 career victories have come via stoppage and he has only seen the scorecards once in his UFC career.

Petr Yan -500 vs. Urijah Faber +360, bantamweights: Faber (35-10) was once the face of the featherweight division, winning the WEC championship and defending it successfully five times. While he remained a big star, becoming champion again was not in the cards. He lost six attempts to win back a championship in WEC and UFC after his title loss to Mike Brown. He only lost two non-title fights from the time he won the WEC title in March 2006. Faber retired after a win over Brad Pickett in December 2016 but came out of retirement this July and scored a knockout win over Ricky Simon in just 46 seconds. He now, unbelievably, could return to a title fight if he defeats the highly regarded Russian. Yan (13-1) is riding an eight-fight winning streak that includes five UFC victories. He is ranked No. 2 at bantamweight in the CBS Sports rankings and a win over Faber is the kind of signature win that could land him in the Octagon with division champ Henry Cejudo.

Marlon Moraes -200 vs. Jose Aldo +160, bantamweights: Aldo (28-5) defeated Faber during his lengthy reign as the top featherweight on the planet. After an 18-fight winning streak, a mega-fight with Conor McGregor ended in disaster for the Brazilian as he lost just 13 seconds into the fight. Aldo won the interim featherweight championship in his next bout, a decision win over Frankie Edgar and was later promoted to full champion status. He lost the belt against Max Holloway and lost the rematch, both by knockout. He is 2-1 since, but the decision to drop to bantamweight has brought controversy as he already struggled to make the 145-pound featherweight limit. Moraes (22-6-1) entered the UFC after an impressive career that saw him capture the WSOF championship and defend it successfully five times. He dropped a split decision to Raphael Assuncao in his Octagon debut before rattling off four consecutive wins, including two by knockout. That run landed him in the cage with Henry Cejudo for the vacant UFC bantamweight championship, losing by knockout in the third round. Moraes is currently ranked No. 5 in the CBS Sports rankings.

Amanda Nunes (c) -340 vs. Germaine de Randamie +270, women's bantamweight championship: Nunes (18-4) defeated de Randamie in November 2013, before the Brazilian established herself as possibly the greatest fighter in the history of women's MMA. Nunes lost her next fight but then rattled off nine straight victories, including beating Ronda Rousey and Cris Cyborg, both by knockout in less than a minute. She captured the bantamweight title with a submission of Miesha Tate while the Cyborg knockout earned her the featherweight title. The names littering her current win streak read like a who's who of the top names in the history of women's MMA: Rousey, Cyborg, Holm, Tate, Shevchenko (twice), Pennington, McMann, Baszler. For de Randamie (9-3) redemption for their first fight will not be easy. She has run through the opposition since that loss, going 5-0 and scoring wins over big names of her own, including Holm, Pennington and Ladd. De Randamie comes from a kickboxing background and that power has shown with three knockouts during her five-fight winning streak. Nunes is the clear No. 1 ranked fighter in the division with de Randamie at No. 2 in the CBS Sports rankings.

Max Holloway (c) -185 vs. Alexander Volkanovski +155, featherweight championship: A 13-fight winning streak for Holloway (21-4) was snapped when he made the decision to move to lightweight to battle Dustin Poirier for the interim title at 155 pounds. He bounced back with a win over Frankie Edgar to defend the featherweight crown. Volkanovski, ranked No. 2, is riding a 17-fight win streak that includes seven wins in the Octagon. In his two most recent fights, he knocked out Chad Mendes and scored a decision win over Aldo. Eleven of his 20 career victories have come via knockout.

Kamaru Usman (c) -185 vs. Colby Covington +155, welterweight championship: When the UFC was pushing the idea of Tyron Woodley as the greatest of all-time in the welterweight division -- this despite Georges St. Pierre's existence -- Usman (15-1) came along and dominated 25 minutes of action in their bout to become the champ. That March fight feels like a lifetime ago, and Usman had, in many ways, faded from the spotlight until Covington (15-1) and his trash talk turned their rivalry into one of the most talked about in MMA. This is a battle of men on lengthy winning streaks, Usman at 14 and Covington at seven, but it's also a battle of egos. Covington has played up a character, for better and for worse, but he has backed up his talk with impressive wins, most recently dominating Robbie Lawler while throwing a record-breaking 541 strikes. Both men have solid amateur wrestling backgrounds and have developed well-rounded games to go along with them. It's an intriguing battle on paper and there will be no disputing the true champion at 170 pounds once the men settle things in the cage.

‘The Falcon and The Winter Soldier’ Set Photos Tease New York City Setting – Heroic Hollywood

Posted on December 18, 2019 by Danzig

You can start the gallery of new posters by clicking "Next".

Here is the synopsis for the show:

Doom Patrolwill premiere on February 15, 2019 exclusively on DC Universe.

Read this article:

'The Falcon and The Winter Soldier' Set Photos Tease New York City Setting - Heroic Hollywood

5 cutting-edge ways companies are leveraging augmented and virtual reality – AdAge.com

Posted on December 18, 2019 by Danzig

One of the hottest trends in advertising right now is the use of augmented reality (AR) or virtual reality (VR). AR and VR can provide greater creative freedom for advertisers, resulting in a product that can reach customers in a way that traditional ad mediums cant always do.

As leaders in their field, the members of Ad Age Collective keep on top of the latest marketing and advertising trends, as well as how to implement them successfully. Below, five of them tell us the most cutting-edge ways they've seen companies leverage augmented and virtual reality in their campaigns.

Brainlab recently announced a partnership with Magic Leap, which leverages AR to help train brain surgeons via interaction with 3D visualizations. Given Magic Leap raised $2.6 billion off the back of a seriously creative communications strategy, this partnership shows the power of bringing together forward-thinking technology and out-of-the-box communications to make an enormous positive impact. - Patrick Ward, Rootstrap

An effective strategy Ive seen companies leverage with a virtual reality experience is one that teases a new product or launch through hidden passageways or corners to show what is coming before giving away the entire secret prior to the official launch. - Jessica Hawthorne-Castro, Hawthorne Advertising

As we know, many consumers buy wine based on the label, and 19 Crimes has used augmented reality to take the label up a notch. The novelty and short videos became a centerpoint of conversation shared around the bottle. And then, via word of mouth, the experience can be perpetuated to friends who haven't yet experienced the brand -- the most efficient form of promotion. - Reid Carr, Red Door Interactive

Walmart created Walmart Academies, a program using VR to improve the employee experience, deliver training and accurately assess workers' skills. It recreates scenarios associates encounter on the floor but in a safe environment. This program is widely successful as its closely aligned with the business goal of delivering shoppers with the best customer experience possible. - Mason Page, Reflect Systems

Porsche had a problem: How do you keep people excited about a car that theyve put a deposit down for, but have never seen in person? For the Taycan, Porsches electric sports car, they created an augmented reality car app that superimposed a model car wherever you pointed your iPad or mobile phone camera. It was like a virtual RC car and it gave fans something to share with their friends and family. - Rex Briggs, Marketing Evolution

Read this article:

5 cutting-edge ways companies are leveraging augmented and virtual reality - AdAge.com

Paramount Inks Multi-Year Pact With Bigscreen For Virtual Reality Distribution – Deadline

Posted on December 18, 2019 by Danzig

Paramount Pictures and San Francisco-based virtual reality startup Bigscreen have set a multi-year agreement that will see select titles from the studio distributed to social VR viewers.

The pact includes the U.S., UK, Canada, Germany, France, Spain, the Netherlands, Sweden, Australia, and Japan.

On Bigscreens platform, users customize personal avatars, hang out in a virtual lobby and voice chat with other movie fans. Films are streamed on screens inside virtual cinemas, providing a social movie watching experience. In addition to 2D screenings, Bigscreen will also show some films in 3D, using rendering technology that it says creates a level of depth and detail not possible with traditional 3D glasses.

Bigscreens virtual reality platform offers a new way for fans to experience films in their homes, said Bob Buchi, President of Worldwide Home Entertainment at Paramount. Were excited to be a part of this experiment using cutting-edge technology to give fans a new entertainment option.

Starting Monday, four new movies per week will premiere in Bigscreen for one-week runs. Titles are delivered to Bigscreen audiences live on a pay-per-view basis, with scheduled showtimes every 30 minutes. Decembers lineup includes Star Trek, Raiders of the Lost Ark and Interstellar.

We are excited to enable fans around the world to hangout, chat, and watch films together in our virtual movie theater, Bigscreen founder and CEO Darshan Shankar said.

Bigscreen can be downloaded for free. Itruns on the Oculus Quest, Oculus Rift, Oculus Go, HTC Vive, Valve Index, all SteamVR headsets, and all Microsoft Windows Mixed Reality headsets.

Founded in 2014, Bigscreen is backed by $14 million in venture funding from lead investors Andreessen Horowitz and True Ventures. It claims to have more than 1 million users of its VR platform, which launched in 2016. The Bigscreen app is often ranked in the top 10 in the app store for Oculus and SteamVR.

Follow this link:

Paramount Inks Multi-Year Pact With Bigscreen For Virtual Reality Distribution - Deadline

Global Healthcare Augmented Reality (AR) and Virtual Reality (VR) Market Set to Reach $10.82 Billion by 2025 – PRNewswire

Posted on December 18, 2019 by Danzig

DUBLIN, Dec. 18, 2019 /PRNewswire/ -- The "Global Healthcare Augmented Reality and Virtual Reality Market by Technology, Offering, Device Type, Application, End-user, and Region 2019-2026: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Global augmented reality and virtual reality market in healthcare industry is expected to reach $10.82 billion by 2025, representing a remarkable 2019-2026 CAGR of 36.1%. Augmented Reality (AR) technology accounts for a larger market share and will grow at 38.38% annually over the forecast years, faster than the Virtual Reality (VR) technology in healthcare domain.

The report provides historical market data for 2015-2018, revenue estimates for 2019, and forecasts from 2020 till 2026.

Highlighted with 82 tables and 79 figures, this 184-page report is based on a comprehensive research of the entire global healthcare AR and VR market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain.

In-depth qualitative analyses include identification and investigation of the following aspects:

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify global healthcare augmented reality and virtual reality market in every aspect of the classification from perspectives of Technology, Offering, Device Type, Application, End-user, and Region.

Based on technology, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.

Augmented Reality (AR)

Virtual Reality (VR)

Based on offering, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.

Hardware

Software

Service

Based on device type, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.

Augmented Reality Devices

Virtual Reality Devices

Based on application, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.

Based on end-user, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.

Geographically, the following regions together with the listed national markets are fully investigated:

For each of the aforementioned regions and countries, detailed analysis and data for annual revenue are available for 2015-2026. The breakdown of all regional markets by country and split of key national markets by Technology, Application, and End-user over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in global healthcare augmented reality and virtual reality market are assayed quantitatively and qualitatively through a Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players

For more information about this report visit https://www.researchandmarkets.com/r/lz61aj

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Global Healthcare Augmented Reality (AR) and Virtual Reality (VR) Market Set to Reach $10.82 Billion by 2025 - PRNewswire

Select Page ::